Investigating the impact of a-synuclein pathology on human embryonic stem cell derived dopaminergic neurons transplanted in an accelerated a-synuclein rat model of Parkinson’s disease
Objective: In this study, we assess how transplanted human embryonic stem cell (hESC) derived dopaminergic (DA) neurons survive, mature, integrate and innervate the host circuitry…Neuroprotective effect of Yerba mate (Ilex paraguariensis) in a Drosophila model of Parkinson ’s disease
Objective: To test the neuroprotective capacity of Yerba Mate (YM) in an in vivo model of Parkinson's disease. Background: Parkinson's disease (PD) is caused by the…Serological analysis of circulating Alpha Synuclein protein levels by Surface Plasmon Resonance (SPR) In Parkinson’s disease
Objective: α-synuclein (α-Syn) is a presynaptic protein whose overexpression or misfolding contributes to the pathophysiology of Parkinson’s disease (PD). This study aims to estimate the…Widespread distribution and abundant accumulation of alpha-synuclein oligomers in multiple system atrophy brain
Objective: To examine the distribution of alpha-synuclein (αSyn) oligomers as an early pathological change in multiple system atrophy (MSA) brains. Background: Although severe neuronal loss…Evaluation of neuroprotection by human ENGRAILED-1 in a chronic AAV-hα-synuclein-A53T (AAV-A53T) rat model of Parkinson Disease
Objective: Investigate the long-term neuroprotective effect of a single bilateral injection of human ENGRAILED1 (hEN1) in a rat α-synuclein model of Parkinson Disease (PD). Background:…Neuritic pathology in Parkinson’s Disease results from loss of anti-oxidant response activity
Objective: To determine the link between α-syn accumulation and neuritic pathology in Parkinson’s Disease (PD). Background: Neurological dysfunction in PD is highly associated with pathological…Role of microRNA-153 and -223 in Parkinson disease
Objective: To assess the therapeutic and diagnostic potential of microRNA (miR)-153 and miR-223 in mice and humans with parkinsonism. Background: Dysregulated miRNAs play a major…A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of Alpha-Synuclein Aggregation
Objective: To evaluate the safety, tolerability and pharmacokinetics of PBT434 in healthy volunteers. Background: PBT434 is a novel, small molecule inhibitor of alpha-synuclein aggregation. In…Maladaptive Nigrovagal Neuronal Plasticity Causes Ascending Alpha-Synucleinopathy in a Novel Environmental Toxin Based Rat Model of Parkinsonism
Objective: Test the hypothesis that unilateral chemogenetic inhibition of the nigrovagal pathway in the subthreshold Paraquat (P) + dietary lectin (L) exposure rat model of…NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson’s Disease: Study Design and Status Update
Objective: To assess the safety and tolerability of nilotinib (150-300 mg once daily) in moderate/advanced Parkinson’s disease (PD). Background: Nilotinib is approved by the FDA…
- « Previous Page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- …
- 70
- Next Page »